Furthermore, increasing evidence has demonstrated that serum BAFF levels both in non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma patients are elevated compared with those of healthy controls, and patient outcome is poorer when serum BAFF levels are higher [15]–[18]. This evidence concerns the gene TNFSF13B and non-Hodgkin lymphoma.